WallStSmart

America Movil SAB de CV ADR (AMX)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

America Movil SAB de CV ADR generates 1342% more annual revenue ($948.44B vs $65.77B). MRK leads profitability with a 13.6% profit margin vs 9.2%. AMX appears more attractively valued with a PEG of 1.18. AMX earns a higher WallStSmart Score of 65/100 (C+).

AMX

Buy

65

out of 100

Grade: C+

Growth: 5.3Profit: 7.0Value: 6.3Quality: 4.0
Piotroski: 6/9Altman Z: 1.37

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 3.3Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AMX.

MRKOvervalued (-13.8%)

Margin of Safety

-13.8%

Fair Value

$97.84

Current Price

$111.38

$13.54 premium

UndervaluedFair: $97.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMX6 strengths · Avg: 8.3/10
Market CapQuality
$80.46B9/10

Large-cap with strong market position

Return on EquityProfitability
21.1%9/10

Every $100 of equity generates 21 in profit

P/E RatioValuation
16.0x8/10

Attractively priced relative to earnings

Operating MarginProfitability
21.3%8/10

Strong operational efficiency at 21.3%

EPS GrowthGrowth
25.8%8/10

Earnings expanding 25.8% YoY

Free Cash FlowQuality
$3.27B8/10

Generating 3.3B in free cash flow

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$277.36B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

AMX3 concerns · Avg: 2.3/10
Revenue GrowthGrowth
2.1%4/10

2.1% revenue growth

Altman Z-ScoreHealth
1.372/10

Distress zone — elevated risk

Debt/EquityHealth
2.531/10

Elevated debt levels

MRK4 concerns · Avg: 3.3/10
P/E RatioValuation
31.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
5.282/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : AMX

The strongest argument for AMX centers on Market Cap, Return on Equity, P/E Ratio. PEG of 1.18 suggests the stock is reasonably priced for its growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : AMX

The primary concerns for AMX are Revenue Growth, Altman Z-Score, Debt/Equity. Debt-to-equity of 2.53 is elevated, increasing financial risk.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

AMX carries more volatility with a beta of 0.28 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

AMX generates stronger free cash flow (3.3B), providing more financial flexibility.

Monitor TELECOM SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AMX scores higher overall (65/100 vs 50/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

America Movil SAB de CV ADR

COMMUNICATION SERVICES · TELECOM SERVICES · USA

Amrica Mvil, SAB de CV provides telecommunications services in Latin America and internationally. The company is headquartered in Mexico City, Mexico.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?